0000000001030569
AUTHOR
G Ficarra
Optimization of the characteristic angles of both front and rear McPherson suspensions on a circular track using multi-body numerical simulation
The research reported in this paper aims to simulate the road-holding of a virtual vehicle using multi-body simulation to estimate both the contact forces between the tyre and ground and the roll motion when cornering. Furthermore, the effect of the characteristic angles on the variation in the forces of the tyre in contact with the ground is studied to determine optimal values for these angles. Emphasis is placed on an average-class vehicle, of which both the external dimensions and mass are chosen appropriately, with a McPherson suspension mounted on both the front and the rear. The characteristic values of the camber and toe-in angles, in both the front and the rear, are optimized for m…
Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review.
Human papillomavirus (HPV) in oral carcinoma (OSCC) and potentially malignant disorders (OPMD) is controversial. The primary aim was to calculate pooled risk estimates for the association of HPV with OSCC and OPMD when compared with healthy oral mucosa as controls. We also examined the effects of sampling techniques on HPV detection rates. Methods: Systematic review was performed using PubMed (January 1966-September 2010) and EMBASE (January 1990-September 2010). Eligible studies included randomized controlled, cohort and cross-sectional studies. Pooled data were analysed by calculating odds ratios, using a random effects model. Risk of bias was based on characteristics of study group, appr…
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…